Welcome!
Ardence Pharma
Broker's Calls
Ardence Pharma deal favourable, analysts keep 'buy' on Hyphens Pharma
Although the incremental net profit contribution is likely negligible near term, the deal presents cross-selling opportunities.
October 23, 2023